The judges for the 2021 will be announced following the opening of the Index to entries for this year. If you would like to be kept up to date, pre-register your company to take part in the Patient Partnership Index 2021 here.
The judges will use a bespoke metric created by OVID Health in partnership with pharmaceutical companies and patient groups to judge (not rank) entries based on industry best practice. The Index covers six themes: engagement; co-creation; empowerment; transparency; innovation and impact.
The expert panel of judges for the Index in 2020 were: PharmaTimes Editor Selina McKee; OVID Health Founder Jenny Ousbey; CEO of Sarcoma UK Richard Davidson; and Director of ABPI Code Engagement Jill Pearcy.
Jenny OusbeyManaging Director, OVID Health
Jenny began her career as a political journalist and has successfully led high-profile national and global campaigns in-house and agency-side. Prior to launching OVID she successfully built up an award-winning healthcare and pharmaceutical communications practice at another agency. She is a former adviser to a government health minister, and has advised a wide range of stakeholders: from global pharmaceutical companies; NHS organisations; healthcare charities; private equity; the independent sector and digital start-ups.
Richard DavidsonChief Executive, Sarcoma UK
Richard joined Sarcoma UK as their Chief Executive in July 2018 after eight successful years at Anthony Nolan. Leading an 80-strong team as the charity’s Director of Engagement, he was responsible for overseeing communications, fundraising and marketing, helping the charity to dramatically increase the recruitment of stem cell donors from 20,000 per year to 80,000. Prior to that he was a Director at health communications agency, MHP and spent 11 years as the Director of Policy and Public Affairs at Cancer Research UK.
Jill PearcyDirector of ABPI Code Engagement, The Association of the British Pharmaceutical Industry
Jill joined the ABPI in August 2018. Her remit is to champion self-regulation across the industry and with stakeholders; to lead development and evolution of the Code; and to assess requirements for, and deliver, services and support around the Code, including managing the ABPI’s delivery of disclosure. Jill has a background in communications and engagement, with a focus on highly-regulated industries at the interface of public and private sectors. She was previously Head of Corporate Communications at HS2 Ltd.
Selina McKeeEditor in Chief, PharmaTimes
Selina is the highly-regarded editor of the industry publication PharmaTimes, a role she took on in 2018. Previous to that she headed up the publications online output and also has a background as a research analyst for Evaluate Pharma. Selina holds a degree in human biology and is passionate about putting patients and innovation at the heart of the pharma industry debate.